{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T18:38:08Z","timestamp":1771612688019,"version":"3.50.1"},"reference-count":31,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,5,14]],"date-time":"2023-05-14T00:00:00Z","timestamp":1684022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1151959"],"award-info":[{"award-number":["APP1151959"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>The risk of transfusion\u2010transmitted hepatitis C virus (HCV) infections is extremely low in Australia. This study aims to conduct a cost\u2010effectiveness analysis of different testing strategies for HCV infection in blood donations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>The four testing strategies evaluated in this study were universal testing with both HCV antibody (anti\u2010HCV) and nucleic acid testing (NAT); anti\u2010HCV and NAT for first\u2010time donations and NAT only for repeat donations; anti\u2010HCV and NAT for transfusible component donations and NAT only for plasma for further manufacture; and universal testing with NAT only. A decision\u2010analytical model was developed to assess the cost\u2010effectiveness of alternative HCV testing strategies. Sensitivity analysis and threshold analysis were conducted to account for data uncertainty.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The number of potential transfusion\u2010transmitted cases of acute hepatitis C and chronic hepatitis C was approximately zero in all four strategies. Universal testing with NAT only was the most cost\u2010effective strategy due to the lowest testing cost. The threshold analysis showed that for the current practice to be cost\u2010effective, the residual risks of other testing strategies would have to be at least 1 HCV infection in 2424 donations, which is over 60,000 times the baseline residual risk (1 in 151 million donations).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The screening strategy for HCV in blood donations currently implemented in Australia is not cost\u2010effective compared with targeted testing or universal testing with NAT only. Partial or total removal of anti\u2010HCV testing would bring significant cost savings without compromising blood recipient safety.<\/jats:p><\/jats:sec>","DOI":"10.1111\/vox.13429","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T05:46:55Z","timestamp":1684129615000},"page":"471-479","source":"Crossref","is-referenced-by-count":3,"title":["Removing hepatitis C antibody testing for Australian blood donations: A cost\u2010effectiveness analysis"],"prefix":"10.1111","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3701-8760","authenticated-orcid":false,"given":"Qinglu","family":"Cheng","sequence":"first","affiliation":[{"name":"Kirby Institute UNSW Sydney  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7827-3661","authenticated-orcid":false,"given":"Veronica C.","family":"Hoad","sequence":"additional","affiliation":[{"name":"Australian Red Cross Lifeblood  Perth Western Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avijoy","family":"Roy Choudhury","sequence":"additional","affiliation":[{"name":"UWA Medical School The University of Western Australia  Perth Western Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0234-4507","authenticated-orcid":false,"given":"Clive R.","family":"Seed","sequence":"additional","affiliation":[{"name":"Australian Red Cross Lifeblood  Perth Western Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8680-922X","authenticated-orcid":false,"given":"Peter","family":"Bentley","sequence":"additional","affiliation":[{"name":"Australian Red Cross Lifeblood  Perth Western Australia Australia"},{"name":"UWA Medical School The University of Western Australia  Perth Western Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophy T. F.","family":"Shih","sequence":"additional","affiliation":[{"name":"Kirby Institute UNSW Sydney  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jisoo A.","family":"Kwon","sequence":"additional","affiliation":[{"name":"Kirby Institute UNSW Sydney  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard T.","family":"Gray","sequence":"additional","affiliation":[{"name":"Kirby Institute UNSW Sydney  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Wiseman","sequence":"additional","affiliation":[{"name":"Kirby Institute UNSW Sydney  Sydney Australia"},{"name":"Department of Global Health and Development London School of Hygiene &amp; Tropical Medicine  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,5,14]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"Kirby Institute UNSW Sydney and Australian Red Cross Lifeblood.Transfusion\u2010transmissible infections in Australia: 2022 surveillance report. Available from:https:\/\/kirby.unsw.edu.au\/report\/transfusion-transmissible-infections-australia-surveillance-report-2022"},{"key":"e_1_2_8_3_1","unstructured":"Kirby Institute UNSW Sydney the Australian Red Cross Blood Service.Transfusion\u2010transmissible infections in Australia: 2020 surveillance report. Available from:https:\/\/kirby.unsw.edu.au\/report\/transfusion-transmissible-infections-australia-surveillance-report-2020"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13024"},{"key":"e_1_2_8_5_1","unstructured":"Centers for Disease Control and Prevention.Blood safety basics. Available from:https:\/\/www.cdc.gov\/bloodsafety\/basics.html"},{"key":"e_1_2_8_6_1","volume-title":"Guidelines for the blood transfusion services in the United Kingdom","year":"2013"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/vox.13430","article-title":"Is dual testing for hepatitis C necessary? Modelling the risk of removing hepatitis C antibody testing for Australian blood donations","volume":"118","author":"Choudhury A","year":"2023","journal-title":"Vox Sang"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2000.40101182.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12943"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12538"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2008.09.001"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0042-9007.2004.00379.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13858"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02877.x"},{"key":"e_1_2_8_15_1","unstructured":"TreeAge Pro2021.TreeAge Software: Williamstown MA United States. Available from:http:\/\/www.treeage.com"},{"key":"e_1_2_8_16_1","volume":"25","author":"Aisyah DN, Shallcross L, Hully AJ, O'Brien A, Hayward A","journal-title":"J Viral Hepat"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0257369"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13013"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.05.008"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365540500532803"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13223"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2010.01378.x"},{"key":"e_1_2_8_23_1","unstructured":"Australian Bureau of Statistics.Deaths year of occurrence age at death age\u2010specific death rates sex states territories and Australia. Available from:https:\/\/www.abs.gov.au\/statistics\/people\/population\/deaths-australia\/2021"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S132072"},{"key":"e_1_2_8_25_1","unstructured":"National Centre in HIV Epidemiology and Clinical Research.Epidemiological and economic impact of potential increased hepatitis C treatment uptake in Australia 2010. Available from:http:\/\/optimamodel.com\/pubs\/hcv%202010.pdf"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-016-0537-0"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.07.005"},{"key":"e_1_2_8_28_1","unstructured":"Pharmaceutical Benefits Advisory Committee.Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (version 5.0). Available from:https:\/\/pbac.pbs.gov.au\/content\/information\/files\/pbac-guidelines-version-5.pdf"},{"key":"e_1_2_8_29_1","unstructured":"Medical Services Advisory Committee.Technical guidelines for preparing assessment reports for the Medical Services Advisory Committee\u2014Service Type: investigative (version 3.0). Available from:http:\/\/www.msac.gov.au\/internet\/msac\/publishing.nsf\/Content\/0BD63667C984FEEACA25801000123AD8\/$File\/InvestigativeTechnicalGuidelines\u2010December\u20102016\u2010Version\u20103.0.pdf"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.2002.130_1.x"},{"key":"e_1_2_8_31_1","unstructured":"Alliance of Blood Operators.Risk\u2010based decision\u2010making framework for blood safety. Available from:https:\/\/www.allianceofbloodoperators.org\/abo\u2010resources\/risk\u2010based\u2010decision\u2010making.aspx"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17224"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.13429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T03:46:23Z","timestamp":1694749583000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.13429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,14]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1111\/vox.13429"],"URL":"https:\/\/doi.org\/10.1111\/vox.13429","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,14]]}}}